Navigation Links
Isis Earns $5 Million Milestone Payment From GSK for Designation of a Development Candidate to Treat an Undisclosed Rare and Serious Disease
Date:7/29/2010

CARLSBAD, Calif., July 29 /PRNewswire-FirstCall/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) announced today that it has earned a $5 million milestone payment from GlaxoSmithKline (NYSE: GSK) related to the designation as a development candidate of a drug to treat an undisclosed rare and serious disease.  Isis will develop the drug to Phase 2 proof-of-concept, at which time GSK has the option to license it.  

"We are pleased to have achieved this milestone so early in our collaboration with GSK.  This alliance is an important step in enhancing our focus on rare disease, and we are excited to move our third drug in this area into our pipeline," said Stanley T. Crooke, M.D., Ph.D., Chairman and Chief Executive Officer of Isis.  "Under this new model of partnership we are able to retain control of this asset to facilitate its rapid development, while benefiting from GSK's expertise and new focus in rare diseases, and financially, from milestone payments even before GSK exercises its license option at Phase 2 proof-of-concept."

In March 2010, Isis entered into a strategic alliance with GSK to develop RNA therapeutics for rare and infectious diseases.  Under the terms of the agreement, which covers up to six programs, Isis received an upfront $35 million payment from GSK and is eligible to receive license fees and milestone payments, totaling nearly $1.5 billion, in the event all six programs are successfully developed for one or more indi
'/>"/>

SOURCE Isis Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Aerospace engineer earns Oak Ridge Associated Universities Ralph Powe Junior Faculty Award
2. InterMune Earns Development Milestone in HCV Protease Inhibitor Collaboration With Roche
3. Advanced Pest Control Earns Quality Pro Designation for General Pest Control Services
4. Professor-turned-producer learns the movie biz
5. Physicians in Europe Rate Novartis #1 on Service Delivery, While Merck Earns Top Honors in the US
6. BioSoteria eLearning Executive Michelle Nolin Flewell Earns Certification
7. iCorps Technologies Earns CompTIA Security Trustmark™
8. Michael Sitaras of SavATree Earns ISA Certified Arborist Designation
9. Wake Forest earns patent for efficient, inexpensive fiber-based solar cells
10. Huifeng Bio-Pharmaceutical (HFGB) Announces USD $1.1 Million Supply Agreement with DNP International Co. Inc.
11. Kiwa Bio-Tech 2nd Quarter Revenues Increase 61.7% to $3 Million, Six Month Revenues Top $5.2 Million
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/16/2015)... Ohio (PRWEB) April 16, 2015 ... Index, overexertion involving an outside source was ranked ... This includes injuries related to lifting, pushing, pulling, ... billion in direct costs. The David Round Company ... is committed to working hard to develop and ...
(Date:4/16/2015)... , April 16, 2015  RegeneRx Biopharmaceuticals, ... announced its U.S. joint venture with G-treeBNT (ReGenTree ... phase 3 clinical trial for the orphan disorder, ... trial for dry eye syndrome (DES) in the ... eye drops, RGN-259/GBT201, this year.  Each of these ...
(Date:4/16/2015)... , April 16, 2015  Scientists from Cleave Biosciences ... on the Horizon," at the American Association for Cancer ... on Sunday, April 19, 2015 from 3:15pm ... Director of Biology, will present new in vivo and ... oral inhibitor of p97, a critical enzyme that controls ...
(Date:4/16/2015)... Fairleigh Dickinson University ( FDU ) ... the Executive Director of the Rothman Institute of ... of the Initiative for Patient Centered Innovation (iPCI), ... the Rothman Institute of Innovation and Entrepreneurship (within ... with FDU’s School of Pharmacy’s Center for Healthcare ...
Breaking Biology Technology:The David Round Company Helps Companies Meet OSHA Standards by Combining Safety, Ergonomics, and Productivity 2RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 2RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 3RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 4RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 5Cleave Biosciences to Participate in Special Session "New Drugs on the Horizon" at AACR Annual Meeting 2015 2Cleave Biosciences to Participate in Special Session "New Drugs on the Horizon" at AACR Annual Meeting 2015 3Dr. Joseph V. Gulfo Named Executive Director of Fairleigh Dickinson University’s Rothman Institute to Spearhead New Initiative for Patient-Centered Innovation (iPCI) 2Dr. Joseph V. Gulfo Named Executive Director of Fairleigh Dickinson University’s Rothman Institute to Spearhead New Initiative for Patient-Centered Innovation (iPCI) 3
... the following Webcast:, What: Neurocrine Biosciences 3rd ... @ 5 p.m. Eastern 2 p.m. Pacific, Where: ... Internet -- Simply log on to the web at the address ... Claudia Woodworth, 858-617-7759 If you are unable to participate during the ...
... demand for health ... economics and market access support, BOSTON, Oct. 28 ... as Vice President., Mr. Barak brings 16 years of ... reimbursement strategies,for drugs, medical devices, and diagnostics in a wide ...
... Company Also Announces Completion of Enrollment in U.S. ... Chronic Hepatitis C,Genotype 1, TAMPA, Fla., Oct. ... today announced the presentation of studies,of nitazoxanide at ... for the Study of Liver Diseases (AASLD), also ...
Cached Biology Technology:Boston Healthcare Appoints Adam Barak as Vice President Enhancing Its International Pricing and Reimbursement Capability 2Romark Laboratories Announces Presentation of New Nitazoxanide Data at 59th Annual AASLD Meeting and 50th Anniversary IASL Meeting in San Francisco 2
(Date:4/13/2015)... 13, 2015  higi, a leading cloud-based consumer engagement ... fully engage with their communities around health and wellness, ... and secure API.  ... accessible, affordable, and convenient vehicle to receive validated health ... The API will allow higi,s trusted partners, ...
(Date:4/6/2015)... Conn. , Apr. 6, 2015 NXT-ID, ... "Company"), a biometric authentication company focused on the ... has filed provisional patent 62/143028 for ... COMMUNICATIONS AND ENERGY TRANSFER  NXT-ID introduces a ... payments. This patent surrounds the use of miniature ...
(Date:4/2/2015)... Fingerprint Cards (FPC) has received ... the distributor World Peace Industrial Group (WPI), part of ... the major part of the shipments will take place ... smartphone manufacturers in China . The ... communicated revenue guidance of + 1 000 MSEK for 2015.  ...
Breaking Biology News(10 mins):higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 2higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 3NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 2NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 3NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 4Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 110 Million 2
... in collaboration with scientists at the University of California, San ... protein switch that plays a crucial role in the development ... 8 issue of the journal Molecular Cell, provide a template ... switch, a protein called Scp1, at will. , "Scp1 is ...
... the plague and some forms of food poisoning "paralyze" the ... to a new study in the September 8, 2006 issue ... researchers found that these bacteria, which belong to the genus ... enzyme. That copycat protein blocks host cells' capacity to change ...
... in the open access journal PLoS Biology, Sagiv Shifman, Jonathan ... the mouse genome--one of the most detailed genetic maps now ... this map, they used two groups of mice: one consisting ... inbred lines (RI). Using the single nucleotide polymorphism (SNP) data ...
Cached Biology News:Detailed 3-D image catches a key regulator of neural stem cell differentiation in action 2Detailed 3-D image catches a key regulator of neural stem cell differentiation in action 3Study illuminates how the plague bacteria causes disease 2Study illuminates how the plague bacteria causes disease 3Mapping the mouse genome 2
Topoisomerase II...
BD BioCoat Fibronectin 150 mm Culture Dishes...
... General description: Dish uses include large-scale ... Compatible with PBA Flexys TM automated ... number is a new product number, created ... showing no availability yet, please order under ...
BD BioCoat Collagen IV 150 mm Culture Dishes...
Biology Products: